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Evidence on everolimus in breast cancer has placed hyperglycemia among the most common high 
grade adverse events. Anthropometrics and biomarkers of glucose metabolism were investigated in a 
observational study of 102 postmenopausal, HR + HER2- metastatic breast cancer patients treated 
with everolimus-exemestane in first and subsequent lines. Best overall response (BR) and clinical benefit 
rate (CBR) were assessed across subgroups defined upon fasting glucose (FG) and body mass index (BMI). 
Survival was estimated by Kaplan-Meier method and log-rank test. Survival predictors were tested in Cox 
models. Median follow up was 12.4 months (1.0–41.0). The overall cohort showed increasing levels of FG 
and decreasing BMI (p < 0.001). Lower FG fasting glucose at BR was more commonly associated with C/
PR or SD compared with PD (p < 0.001). We also observed a somewhat higher BMI associated with better 
response (p = 0.052). More patients in the lowest FG category achieved clinical benefit compared to the 
highest (p < 0.001), while no relevant differences emerged for BMI. Fasting glucose at re-assessment was 
also predictive of PFS (p = 0.037), as confirmed in models including BMI and line of therapy (p = 0.049). 
Treatment discontinuation was significantly associated with changes in FG (p = 0.014). Further research 
is warranted to corroborate these findings and clarify the underlying mechanisms.
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The mammalian target of rapamycin (mTOR) inhibitor everolimus has been approved in combination with 
exemestane for treatment of hormone receptor-positive HER2-negative (HR + HER-) advanced breast cancer 
after failure of treatment with letrozole or anastrozole. Results from the phase III BOLERO-2 trial demonstrated 
that everolimus and exemestane provide significant clinical benefit to patients with advanced HR + breast cancer. 
Although everolimus is generally well tolerated, as with most therapies administered in an advanced cancer set-
ting, drug-related adverse events (AEs) inevitably occur1.
In the BOLERO-2 trial, hyperglycemia was listed among the most common grade 3 or 4 AEs (4% vs <1%, 
in the experimental and control arm, respectively)1. As a common toxicity associated with treatment with 
mTOR inhibitors, hyperglycemia is generally quite efficiently managed and pharmacologically controlled, with 
a low incidence of treatment discontinuation in the BOLERO-2 and subsequent studies of everolimus in breast 
cancer1–5.
Some considerations stem from the critical appraisal of the aforementioned literature. First, in none of these 
studies data on hyperglycemia were framed and interpreted in a wider context including measures of generalized 
and/or visceral obesity, e.g., body mass index (BMI) and waist circumference, respectively. A sound rationale to 
this approach may be found in the well established link between obesity and hyperglycemia and the combined 
effects of adiposity and hyperglycemia on patients’ important outcomes in HR + breast cancer6–8. In addition, 
previous experiences on the onset of selective toxicities when using targeted agents in the metastatic setting 
encourage evaluating hyperglycemia and, more generally, alterations of indicators of energetic metabolism in 
light of treatment efficacy9,10. Indeed, as a mTOR inhibitor, everolimus exerts its action on a target placed within 
a particularly complex network of pathways involved in the regulation of both the metabolic profile of the host 
and breast cancer development and progression. In these regards, the existence of regulatory loops between 
the insulin-like growth factor-1 receptor (IGF-1R)/insulin receptor substrate-1 (IRS-1) axis and the adenosine 
monophosphate–activated protein kinase (AMPK)/mTOR/protein-kinase 1 p70-S6 (S6K1) signaling cascade is 
well documented11. On this basis, it might be appropriate speculating that the efficacy of everolimus at a single 
patient level might be at least partly modulated by the dynamic equilibrium reached by these two axes follow-
ing this drug administration. We thus speculated on the predictive role of anthropometric indicators of general 
adiposity, i.e., body mass index (BMI), and circulating biomarkers of glucose metabolism, i.e., fasting glucose, 
on treatment outcomes and verified the stated hypothesis in an observational, multicentre study of HR + HER2- 
advanced breast cancer patients treated with everolimus and exemestane in first and subsequent lines of therapy 
(the EverExt study).
Methods
Six cancer institutions located in the Lazio region, Central Italy, contributed patients to our study. Prior to any 
study procedure, the study protocol was examined and approved by the Institutional Review Board at each of 
the participating centers, namely, the Regina Elena National Cancer Institute, Policlinico Sant’Andrea, Campus 
Bio-Medico University of Rome, ASL of Frosinone, G. d’Annunzio University, and San Giovanni Calibita 
Fatebenefratelli Hospital. A written informed consent was secured from each study participant. Our study was 
conducted in accordance with the Declaration of Helsinki.
Patients eligible to enter our study were postmenopausal women aged at least 18 years, with histologically con-
firmed, HR + HER2-advanced BC, and with an indication to treatment with everolimus and exemestane accord-
ing to current indications and recommendations. At least one measurable or evaluable lesion had to be detectable. 
Further required criteria were an ECOG Performance Status (PS) of 0–2, adequate bone marrow, coagulation, 
liver, and renal function, ability to understand and willingness to sign a written informed consent. Exclusion cri-
teria were previous diagnosis of other malignancies, except adequately treated non-melanoma skin cancer and/
or curatively treated in-situ cancer of the cervix, symptomatic brain metastases, and any medical condition which 
might have interfered with safe participation in the study.
Eligible and consenting patients underwent assisted administration of questionnaires in course of face-to-face 
interviews to collect data on demographics and anthropometrics. FG assessment was performed in overnight 
fasting conditions both at baseline and in course of therapy. Data on the treatment in course of administration 
and related outcomes were prospectively collected, while records on the pathological features and previous treat-
ment were retrieved by specifically trained research assistants under the supervision of the medical oncologists 
involved in the project.
To our study purposes, BMI was computed as the ratio between weight in kilograms and height in meters 
squared. Objective response (OR) was evaluated based on the Response Evaluation Criteria in Solid Tumours 
(RECIST) version 1.1. The best overall response (BR) was defined as the best response recorded from the start 
of the treatment under investigation until disease progression. Clinical benefit rate (CBR) was addressed as the 
percentage of patients with shrinking tumours or stable disease for at least 6 months. Progression free survival 
(PFS) was defined as the time elapsed between treatment start and interruption due to disease progression or 
death from any cause. Overall survival (OS) was defined as the time from the start of treatment to patient death 
from any cause. Toxicity was evaluated according to the National Cancer Institute Common Terminology Criteria 
for AE (NCI CTCAE) version 4.0.
Descriptive characteristics were analyzed for the overall study population and for all the variables of interest. 
We used means and standard deviations for continuous data and frequencies and percentage values for categorical 
data. Existing differences between mean values were evaluated using the Mann-Whitney or Kruskal-Wallis test, 
depending on the number of groups compared. Survival data were analyzed using the Kaplan-Meier method and 
differences among curves evaluated by log-rank test. The impact of anthropometric and metabolic biomarkers on 
survival was tested in Cox proportional Hazards models including variables testing significant at the univariate 
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or selected on the basis of the relevance to the outcomes of interest. Statistical analyses were performed with SPSS 
statistical software version 20 (SPSS inc., Chicago IL, USA).
Results
The flow chart of our study is shown in Fig. 1. At the six cancer institutes participating in our study, 117 patients 
were screened and judged eligible based on the inclusion criteria fully reported in the methods section. Among 
them, 15 patients were subsequently excluded due to missing data on FG in course of follow up. Thus, 102 patients 
contributed data to the final analysis.
Patients’ descriptive characteristics. Our study participants’ characteristics are summarized in Table 1. 
In brief, mean age at diagnosis and baseline height, weight and BMI were 60.9 ± 10.1 years, 159.6 ± 6.2 cm, 
69.1 ± 14.1 Kg, and 27.1 ± 5.6, respectively. Baseline values of FG were 101.2 ± 18.8, the mean number of cycles 
of everolimus and exemestane actually received was 9.0 ± 7.0, which in 30 (29.4%) patients were administered in 
first line. Overall, when comparing baseline values of FG and BMI with those assessed at the latest follow up for 
the entire study cohort, our data showed a significant trend towards increasing FG and decreasing BMI. Baseline 
vs final values of FG and BMI were 101.17 ± 18.83 vs 111.69 ± 28.82, p < 0.001 and 27.15 ± 5.58 vs 26.36 ± 5.59, 
p < 0.001, respectively. These differences remained significant when comparing means adjusted by number of 
cycles administered (99.93 ± 17.3 vs 107.3 ± 25.2, p < 0.001 and 27.26 ± 5.25 vs 26.43 ± 5.49, p < 0.001).
Fasting glucose and BMI at the time of disease reassessment and objective response evalua-
tion. In Table 2, FG and BMI at the time of BR assessment were compared across groups defined upon BR and 
CBR. The mean values of FG and BMI were weighted against the number of cycles administered. Results showed 
significantly lower levels of FG at BR in group 1, i.e., in patients whose BR was either a CR/PR or SD, compared 
to group 2, i.e., patients whose disease progressed (108.9 ± 29.3 vs 122.6 ± 38.0, p < 0.001). Data also showed a 
suggestion for higher BMI values in the group of patients with CR/PR or SD (26.9 ± 5.3 vs 26.1 ± 6.4, p = 0.052). 
When distinguishing patients into three3 subgroups including women with CR/PR, cases with SD and those with 
Figure 1. Study flow chart.
mean ± SD
Age (years) 60.9 ± 10.1
Weight (Kg) 69.1 ± 14.1
Height (cm) 159.6 ± 6.2
BMI (Kg/m2) 27.1 ± 5.6
Fasting glucose (mg/dl) 101.2 ± 18.8
Number of cycles 9.0 ± 7.0
Line of therapy* N (%)
1 30 (29.4)
>1 66 (64.7)
Table 1. Baseline characteristics of the study participants (N:102). *6 missing.
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progressive disease, results on FG were confirmed and those on BMI were statistically reinforced (supplementary 
Table 1). Consistently with what observed when addressing BR, a significantly higher number of patients in the 
lowest category of FG achieved CB compared to their counterpart (61 vs 41, p < 0.001), while there were no rele-
vant differences in terms of BMI.
Survival analysis. Figure 2 illustrates PFS by levels of FG at BR. The cutoff of 107 represents the median 
value of FG at BR in the overall study population. At 18 months, 17.1% of patients whose FG at BR was in the 
lowest category were free from disease progression, compared with 8.6% of women in the highest FG category 
(p = 0.037), with median PFS and 95% CI being 9.50 (6.62–12.37) and 6.57 (3.85–9.29) months, respectively. This 
result was confirmed in uni- and multivariate analyses including BMI at BR and line of therapy (p = 0.040 and 
p = 0.049, for uni- and multivariate models, respectively) (Table 3). Conversely, there was no impact of BMI at BR 
on the best objective response ever achieved (p = 0.169), with median PFS and 95% CI being 7.39 (3.42–11.36) 
and 9.33 (8.27–10.36) months in patients whose BMI at BR was in the lowest and highest category as defined 
upon the median value of 26.4, respectively. Neither FG nor BMI impacted OS (p = 0.89 and p = 0.17, respec-
tively) (data available upon request).
Toxicity. When addressing toxicity, data from 12 patients who dismissed treatment due to AE other than 
altered glucose levels were explored in light of changes in FG over the study period (final FG minus baseline FG/
baseline FG). Changes in FG were significantly more pronounced in patients who quit treatment due to AEs other 
than hyperglycemia than in women who continued treatment (p = 0.014), while changes in BMI seemed not to 
affect discontinuation due to toxicity (p = 0.260).
Discussion
In the proposed study, we assessed the predictive role of BMI and FG on efficacy and toxicity outcomes in 102 
postmenopausal patients with HR + HER2−, metastatic BC treated with everolimus and exemestane at six can-
cer centers located in the Lazio region, centre Italy. We observed a significant trend towards increasing FG and 
Best Response
No PD2 PD2
Mann-WhitneyN = 76 N = 26
Mean* ± SD Mean* ± SD p-value
Fasting glucose at BR 108.9 ± 29.3 122.6 ± 38.0 <0.001




N = 41 N = 41
Mean* ± SD Mean* ± SD p-value
Fasting glucose at BR 108.2 ± 29.5 120.5 ± 33.0 <0.001
BMI at BR 26.8 ± 5.4 26.9 ± 5.4 0.895
Table 2. Best response (BR) and Clinical Benefit (CB) by fasting glucose and BMI1 at the time of BR assessment 
(N:102). 1BMI: body mass index. 2PD: Disease Progression. *Mean weighted by number of cycles administered.
Figure 2. Progression free survival (PFS) by fasting glucose (FG) at best response (BR) (N:102).
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decreasing BMI in the overall study population. We also found significant evidence of association of FG levels 
assessed at the time of BR recording with BR and CBR, with lower levels of FG being associated with better out-
comes. There also was a suggestion for an association between higher BMI at BR and CR/PR or SD, which was 
statistically reinforced when comparing three3 distinct categories of OR, i.e., CR/PR vs SD vs PD, instead than 
two2, i.e., CR/PR/SD vs PD. or. We also found evidence in support of longer PFS in patients whose FG levels 
were in the lowest category defined upon the median FG value for the overall study population. This result was 
confirmed in Cox models including line of therapy and BMI. None of the exposures of interest seemed to affect 
OS. In addition, changes in FG over the course of treatment were significantly more pronounced in patients who 
suspended treatment due to toxicity other than hyperglycemia.
Over the past few years, the evidence concerning the efficacy and safety of the treatment of interest has 
immensely grown with large and consistent data being provided from both randomized clinical trials and real 
practice1–5,12. Data from the BOLERO-2 phase III clinical trial and the BALLET expanded access program (EAP) 
have been particularly informative on the efficacy and feasibility of this treatment, respectively1,5. With specific 
regards to the exposures of interest, i.e., FG and BMI, we observed significant evidence of increasing FG and 
decreasing BMI in the overall population. The closest evidence which may attain to our results is concerning 
the incidence and time course of hyperglycemia in trials of everolimus and exemestane in breast cancer. In the 
BOLERO-2 trial, hyperglycemia was defined based on the criteria stated by the American Diabetes Association 
(ADA), namely, fasting glucose levels >130 mg/dL or postprandial levels >180 mg/dL. Thirteen13 vs 2 events 
were recorded in the experimental and control arm, respectively. Four percent (4%) of these AE were graded 3 
or 4 in the patients treated with EverExt, while the reported percentage was inferior to 1(˃1%) in patients having 
received exemestane and placebo1–13. When focusing on elderly patients enrolled in BOLERO-2 trial, hypergly-
cemia was again listed among the most commonly observed grade 3 or 4 AEs (≥5%) in patients from the exper-
imental arm, along with stomatitis, fatigue, dyspnea, anemia, and increased gamma-glutamyltransferase levels, 
which were similar across age groups2. Based on the data published subsequently by Rugo and co-authors, 9% 
of patients in the experimental arm and 10% in the control arm exhibited diabetes mellitus or impaired glucose 
tolerance on study entrance. During the study, 11% of the patients in the experimental arm developed grade ≥2 
hyperglycemia or newly-onset diabetes mellitus compared with 2% of patients in the control arm. The incidence 
of all-grade hyperglycemia and new-onset diabetes mellitus was higher in the experimental group than in the 
control arm (16% versus 3%, respectively), with grade 3 or 4 events being observed in 6% and 1% of patients, 
respectively5. Ravaud and colleagues carried out an individual patient data meta-analysis including data from five 
phase 2/3 studies of patients with solid tumours treated with everolimus not including breast cancer. Overall, 945 
and 938 patients were evaluable for efficacy and safety, respectively. Hyperglicemia occurring in course of treat-
ment and lipid alterations were grouped within the same category and globally referred to as “metabolic events”. 
Overall, results from this meta-analysis support the association between higher everolimus exposure and more 
pronounced tumour reduction, longer PFS and increased risk of high-grade pulmonary, stomatitis and metabolic 
events14. The authors also openly refer to the paucity of data currently available from the literature to support or 
adverse the hypothesis of a relationship between AEs and efficacy of mTOR inhibitors. Supportive evidence is 
provided by a retrospective analysis of 46 patients with renal cell carcinoma (RCC) treated with everolimus (N: 
25) or temsirolimus (N: 21). In these patients, a SD was reported in 85.7% of the patients who experienced pneu-
monitis (N:14) versus 43.8% of those who did not (N:32)15. A larger retrospective analysis including data of 310 
patients with RCC having received a mTOR inhibitor showed that non-infectious pneumonitis had a predictive 
role on OS, with better outcome in patients having developed this AE16. In addition, data from the meta-analysis 
from Ravaud and co-authors seem to be consistent with results from these latter studies, in that everolimus expo-
sure was significantly associated with high grade pulmonary, metabolic and stomatitis AEs and reduced tumour 
size14. Pantano and colleagues have recently addressed the changes of lipid metabolism in a case series of 117 
patients with advanced renal cell carcinoma treated with everolimus. Their results showed a predictive role of the 
combined rising of cholesterol and tryglicerides on treatment outcomes, with median time to progression being 
significantly longer in the subgroup of patients who showed this metabolic alteration in course of treatment com-
pared to those who did not (10.9 vs 5.9 months, respectively, p = 0.003)17.
We also observed evidence of association of FG levels assessed at the time of BR recording with BR and 
CBR, with lower levels of FG being associated with better outcomes. In addition, longer PFS was associated with 
lower FG levels in uni- and multivariate analysis. Our findings concerning the predictive role of FG and BMI on 
treatment outcomes in the population of interest are novel. Such novelty can be traced both in the hypothesis 
stated and results obtained. Indeed, previous studies of everolimus in breast cancer have repeatedly addressed 
alterations in circulating levels of FG within the context of fasting or postprandial hyperglycemia. However, the 
statistics provided are essentially descriptive and no prior attempts to investigate the potential impact of such 
abnormalities on treatment outcomes have been pursued. In addition, our data on FG were integrated by the 
Univariate Analysis Multivariate Analysis
HR (95%CI) p-value HR (95%CI) p-value
Fasting Glucose at Best Response 1.70 (1.02–2.83) 0.040 1.69 (1.00–2.84) 0.049
BMI at Best Response 0.78 (0.47–1.28) 0.321 0.75 (0.45–1.25) 0.269
Line of Therapy (1 vs >1) 1.29 (0.74–2.24) 0.369 1.16 (0.66–2.04) 0.596
Table 3. Uni- and multivariate analysis of factors associated progression free survival (PFS) in the EverExt 
study. BMI: Body Mass Index. HR: Hazard Ratio. CI: Confidence Interval.
www.nature.com/scientificreports/
6Scientific RepoRts | 7: 10597  | DOI:10.1038/s41598-017-10061-2
repeated collection of anthropometrics, which were also evaluated in ad hoc analysis and included in multivariate 
models of FG. Data were collected prospectively by specifically trained research personnel with an active role in 
clinical practice. This increases our confidence in our data quality and overall reliability of this study results18,19.
Our study also has some limitations. Among them, the observational nature of our findings, which invites 
caution in results interpretation and imposes limits to their generalizability. This is a common features of sev-
eral studies carried out by our group, which may anyway be outweighed by their potentialities in terms of their 
“hypothesis generating” potentials10–23. We also acknowledge the restricted number of exposures evaluated, i.e., 
fasting glucose and BMI only, as predictors of treatment outcomes in our study population. We are aware of the 
need for a more comprehensive evaluation which including, though not limited to, the systematic estimation of 
parameters related to the regional fat tissue representation, e.g., arms’ fat, legs’ fat and trunk fat. We could not find 
any evidence in support of an association between the exposures of interest and OS. This may at least partly be 
dependent on the relatively short length of follow up, with the median and range being 12 (1.0–4.1) months. In 
the hypothesis of future studies with a longer period of observation, the potential role of lines of therapy admin-
istered following everolimus exemestane should be considered in analysis of OS, along with punctual data on the 
number of lines and agents administered. In our study, FG measurements were not centralized at the institutional 
labs of the participating centres. When conceiving the study, we relied on the use of external laboratories for the 
repeated assessment of FG of the consenting participants. Notwithstanding the superior quality of any form of 
centralized assessment, our choice helped avoid excessive burden for the institutional labs both in terms of time 
and economic resources, which, given the spontaneous nature of our study, were limited. At the same time, our 
decision helped control the number of visits at the participating centres, thus maximizing the rate of acceptance 
and increasing our study feasibility both at an institutional and patient level.
Conclusions
In summary, we conducted an observational, prospectively designed study of 102 metastatic, HR + HER2−, met-
astatic BC patients treated with everolimus and exemestane in first and subsequent lines of therapy at six Italian 
cancer centres. Data analysis revealed a predictive role of FG and BMI on treatment outcomes, with lower FG 
levels recorded at the time of BR being associated with better OR, CBR and longer PFS. Some evidence of asso-
ciation of lower BMI at BR with better outcomes was also observed. Similarly, altered FG seemed to be more 
common in patients who dismissed treatment due to AEs other than hyperglycemia. Whether or not alterations 
in energetic metabolism linked to the use of everolimus may significantly impact this drug efficacy and its safety 
profile remains an open question. Evidence from the EvereExt study is suggestive but in need of extensive and 
multidisciplinary integrations. Future studies within this pipeline have been planned, with a specific focus on 
the molecular mechanisms underlying the phenomena observed. We will considerably expand the spectrum of 
circulating biomarkers and include FG, insulin, and insulin like growth factor I, and indicators of general and 
visceral adiposity, i.e., BMI and waist circumference, and measures of regional fat distribution, e.g., arms’ fat, legs’ 
fat and trunk fat In addition, collection of genomics and trascriptomics data on the components of key signaling 
pathways with a mutual role in breast oncogenesis and glucose homeostasis, e.g. PI3K/AKT and JUN/MAPK will 
be of pivotal importance in clarifying the underlying molecular mechanisms24,25.
Methods
Six cancer institutions located in the Lazio region, Central Italy, contributed patients to our study. Prior to any 
study procedure, the study protocol was examined and approved by the Institutional Review Board at each of 
the participating centers. Patients eligible to enter our study were postmenopausal women aged at least 18 years, 
with histologically confirmed, HR + HER2− advanced BC, and with an indication to treatment with everolimus 
and exemestane according to current indications and recommendations. At least one measurable or evaluable 
lesion had to be detectable. Further required criteria were an ECOG Performance Status (PS) of 0–2, adequate 
bone marrow, coagulation, liver, and renal function, ability to understand and willingness to sign a written 
informed consent. Exclusion criteria were previous diagnosis of other malignancies, except adequately treated 
non-melanoma skin cancer and/or curatively treated in-situ cancer of the cervix, symptomatic brain metastases, 
and any medical condition which might have interfered with safe participation in the study.
Eligible and consenting patients underwent assisted administration of questionnaires in course of face-to-face 
interviews to collect data on demographics and anthropometrics. FG assessment was performed in overnight 
fasting conditions both at baseline and in course of therapy. Data on the treatment in course of administration 
and related outcomes were prospectively collected, while records on the pathological features and previous treat-
ment were retrieved by specifically trained research assistants under the supervision of the medical oncologists 
involved in the project.
To our study purposes, BMI was computed as the ratio between weight in kilograms and height in meters 
squared. Objective response (OR) was evaluated based on the Response Evaluation Criteria in Solid Tumours 
(RECIST) version 1.1. The best overall response (BR) was defined as the best response recorded from the start 
of the treatment under investigation until disease progression. Clinical benefit rate (CBR) was addressed as the 
percentage of patients with shrinking tumours or stable disease for at least 6 months. Progression free survival 
(PFS) was defined as the time elapsed between treatment start and interruption due to disease progression or 
death from any cause. Overall survival (OS) was defined as the time from the start of treatment to patient death 
from any cause. Toxicity was evaluated according to the National Cancer Institute Common Terminology Criteria 
for AE (NCI CTCAE) version 4.0.
Descriptive characteristics were analyzed for the overall study population and for all the variables of interest. 
We used means and standard deviations for continuous data and frequencies and percentage values for categor-
ical data. Existing differences between mean values were evaluated using the Mann-Whitney or Kruskal-Wallis 
test, depending on the number of groups compared. Survival data were analyzed using the Kaplan-Meier method 
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and differences among curves evaluated by log-rank test. The impact of anthropometric and metabolic biomark-
ers on survival was tested in Cox proportional Hazards models including variables testing significant at the uni-
variate or selected on the basis of the relevance to the outcomes of interest. Statistical analyses were performed 
with SPSS statistical software version 20 (SPSS inc., Chicago IL, USA).
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